{
    "nct_id": "NCT03955939",
    "official_title": "A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy",
    "inclusion_criteria": "* Participant must have hormone receptor positive and HER2 negative metastatic breast cancer\n* Participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor\n* Participant must be able and willing to undergo mandatory tumor biopsy\n* Participant must have normal organ function\n* Participant must be able to swallow capsules\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant must not have had prior chemotherapy for mBC. Chemotherapy in the adjuvant/neoadjuvant setting is permitted\n* Participant must not be currently enrolled in a clinical study\n* Participant must not have another serious medical condition\n* Participant must not have previously received an aurora kinase inhibitor",
    "miscellaneous_criteria": ""
}